Breast Cancer Clinical Trial

Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors

Summary

The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.

View Full Description

Full Description

This project will determine the efficacy of vitamin D3 supplements for reducing side effects of treatment with aromatase inhibitors in women with a history of breast cancer that have no evidence of current disease. The aromatase inhibitors (AI) have become a critical component of adjuvant therapy for this population, but they cause bone pain, joint pain, joint stiffness, and muscle weakness in approximately 40% of patients. These symptoms, referred to as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), decrease quality of life and medication adherence. Identifying effective ways to decrease these symptoms may allow for longer and more adherent medication use and thus may improve disease-free survival. We hypothesize that vitamin D3 may decrease symptoms associated with the use of aromatase inhibitors.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥ 18 years
Women with a history of stage I-IIIa invasive breast cancer
History of hormone-receptor positive cancer (either ER + or PR + or both)
Are prescribed and are taking anastrozole, letrozole or exemestane for at least one month and have at least 7 months of AI treatment remaining
Are experiencing AIMSS

Exclusion Criteria:

Unable to read or understand English
History of psychiatric disability affecting informed consent or compliance with drug intake
Malabsorption syndrome or inability to take oral medication
Has less than 7 months of AI therapy remaining

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

116

Study ID:

NCT01509079

Recruitment Status:

Completed

Sponsor:

HealthPartners Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Park Nicollet Frauenshuh Cancer Center
Minneapolis Minnesota, 55416, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

116

Study ID:

NCT01509079

Recruitment Status:

Completed

Sponsor:


HealthPartners Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider